Filing Details

---

---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)* 

 

Keryx Biopharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

492515101

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Except as otherwise provided herein, beneficial ownership information contained herein is given as of the date listed above. 

 

 

	ABRAMS CAPITAL, LLC
	By:	/s/ David Abrams
		Name:	David Abrams
		Title:	Managing Member

 

	ABRAMS CAPITAL MANAGEMENT, LLC
	By:	/s/ David Abrams
		Name:	David Abrams
		Title:	Managing Member

 

	ABRAMS CAPITAL MANAGEMENT, L.P.
	By: Abrams Capital Management, LLC
	Its General Partner
	By:	/s/ David Abrams
		Name:	David Abrams
		Title:	Managing Member

 

	David Abrams
	By:	/s/ David Abrams
		Name:	David Abrams
		Title:	Individually